Bone Healing During Ninlaro Exposure

Inclusion Criteria: * Symptomatic Multiple Myeloma according to the IMWG criteria. * Detectable osteolysis on low dose CT (at least 5 mm in size). * Stable disease, defined as no signs of progressive disease for three months without anti myeloma treatment. * Achieved, partial response or better, during last line of therapy. * Signed informed consent. * Age ≥ 18 years. * Remaining life expectancy ≥ 6 months. * ECOG performance status 0-2. Female patients who * Are postmenopausal for at least 1 year before the screening visit, OR * Are surgically sterile, OR * If they are of childbearing potential, agree to practice 2 effective methods of contraception, simultaneously, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception). Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following * Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception). Exclusion Criteria: * Treatment with Denosumab within the last 4 weeks. * Known concurrent malignancy (last five years), excluding skin cancer. * Known hypersensitivity to Ixazomib. * Central nervous system involvement. * Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive Pregnant or lactating women * Absolute neutrophil count \< 1,000mm3 without growth factor support. * Platelet count \< 75,000/mm3. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before inclusion -Total bilirubin \> 1.5 x the upper limit of the normal range. * Alanine aminotransferase \> 3 x upper limit of the normal range. * Calculated creatinine clearance \< 30 mL/min (using the Cockcroft-Gault equation). * Total bilirubin \> 1.5 the upper limit of the normal range (ULN). * Radiotherapy within 14 days before inclusion. * Major surgery within 14 days before inclusion. * Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, uncontrolled congestive heart failure, unstable angina, or myocardial infarction within the past 6 months. * Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or use of St. John's wort. * Peripheral neuropathy grade 1 with pain or grade 2. * Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout its. * Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of Ixazomibzomib including difficulty swallowing. * Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.